<https://helda.helsinki.fi>

Autophagy Regulates the Liver Clock and Glucose Metabolism by Degrading CRY1

Toledo, Miriam

2018-08-07

Toledo , M , Batista-Gonzalez , A , Merheb , E , Aoun , M L , Tarabra , E , Feng , D ,
Sarparanta , J , Merlo , P , Botre , F , Schwartz , G J , Pessin , J E & Singh , R 2018 , '
Autophagy Regulates the Liver Clock and Glucose Metabolism by Degrading CRY1 ' , Cell
Metabolism , vol. 28 , no. 2 , pp. 268-+ . <https://doi.org/10.1016/j.cmet.2018.05.023>

<http://hdl.handle.net/10138/304178>

<https://doi.org/10.1016/j.cmet.2018.05.023>

publishedVersion

Downloaded from Helda, University of Helsinki institutional repository.

This is an electronic reprint of the original article.

This reprint may differ from the original in pagination and typographic detail.

Please cite the original version.

Cell Metabolism

Autophagy Regulates the Liver Clock and Glucose Metabolism by Degrading CRY1

Graphical Abstract

Authors

Miriam Toledo, Ana Batista-Gonzalez, Emilio Merheb, ..., Gary J. Schwartz, Jeffrey E. Pessin, Rajat Singh

Correspondence

rajat.singh@einstein.yu.edu

In Brief

Toledo et al. show that autophagy controls the liver clock by timely degradation of a circadian protein cryptochrome 1 (CRY1). CRY1 lowers glucose production in liver and its timely removal by autophagy allows glucose production. Obesity accentuates CRY1 degradation by autophagy, increasing glucose production and blood sugar levels.

Highlights

- Core circadian proteins are temporally degraded by lysosomes
- Loss of autophagy promotes CRY1 accumulation and disrupts the circadian clock
- Autophagy drives gluconeogenesis by degrading CRY1
- LIR motifs link CRY1 degradation to regulation of glucose homeostasis

Autophagy Regulates the Liver Clock and Glucose Metabolism by Degrading CRY1

Miriam Toledo,^{1,2} Ana Batista-Gonzalez,^{1,2} Emilio Merheb,³ Marie Louise Aoun,^{1,9} Elena Tarabra,¹ Daorong Feng,¹ Jaakko Sarparanta,^{1,2,10} Paola Merlo,⁵ Francesco Botrè,^{5,6} Gary J. Schwartz,^{1,4,7,8} Jeffrey E. Pessin,^{1,2,7,8} and Rajat Singh^{1,2,7,8,11,*}

¹Department of Medicine, Albert Einstein College of Medicine, Bronx, NY 10461, USA

²Department of Molecular Pharmacology, Albert Einstein College of Medicine, Bronx, NY 10461, USA

³Department of Biochemistry, Albert Einstein College of Medicine, Bronx, NY 10461, USA

⁴Department of Neurology and Neuroscience, Albert Einstein College of Medicine, Bronx, NY 10461, USA

⁵Laboratorio Antidoping, Federazione Medico Sportiva Italiana, Largo Giulio Onesti 1, Rome, RM 00197, Italy

⁶Department of Experimental Medicine, "Sapienza" University of Rome, Viale Regina Elena 324, Rome, RM 00161, Italy

⁷Institute for Aging Research, Albert Einstein College of Medicine, Bronx, NY 10461, USA

⁸Diabetes Research Center, Albert Einstein College of Medicine, Bronx, NY 10461, USA

⁹Present address: Lebanese American University, Gilbert and Rose-Marie Chagoury School of Medicine, PO Box 36, Byblos, Lebanon

¹⁰Present address: Folkhälsan Institute of Genetics and Department of Medical Genetics, University of Helsinki, Haartmaninkatu 8, 00290 Helsinki, Finland

¹¹Lead Contact

*Correspondence: rajat.singh@einstein.yu.edu

<https://doi.org/10.1016/j.cmet.2018.05.023>

SUMMARY

The circadian clock coordinates behavioral and circadian cues with availability and utilization of nutrients. Proteasomal degradation of clock repressors, such as cryptochrome (CRY)1, maintains periodicity. Whether macroautophagy, a quality control pathway, degrades circadian proteins remains unknown. Here we show that circadian proteins BMAL1, CLOCK, REV-ERB α , and CRY1 are lysosomal targets, and that macroautophagy affects the circadian clock by selectively degrading CRY1. Autophagic degradation of CRY1, an inhibitor of gluconeogenesis, occurs in a diurnal window when rodents rely on gluconeogenesis, suggesting that CRY1 degradation is time-imprinted to maintenance of blood glucose. High-fat feeding accelerates autophagic CRY1 degradation and contributes to obesity-associated hyperglycemia. CRY1 contains several light chain 3 (LC3)-interacting region (LIR) motifs, which facilitate the interaction of cargo proteins with the autophagosome marker LC3. Using mutational analyses, we identified two distinct LIRs on CRY1 that exert circadian glycemic control by regulating CRY1 degradation, revealing LIRs as potential targets for controlling hyperglycemia.

INTRODUCTION

The circadian clock synchronizes behavioral and circadian cues with nutrient availability and energy metabolism (Bass and Takahashi, 2010; Perelis et al., 2015). Disrupting circadian rhythm contributes to development of type II diabetes (Marcheva

et al., 2010). The mammalian clock consists of complex feedback loops wherein heterodimeric complexes of transcription factors CLOCK (circadian locomotor output cycles kaput) and BMAL1 (brain and muscle Arnt-like protein 1) initiate expression of period (PER)1/2 and cryptochrome (CRY)1/2, which repress their transcriptional activity (Darlington et al., 1998; Gekakis et al., 1998; Griffin et al., 1999; Kume et al., 1999; Sangoram et al., 1998). Expression of *Bmal1* is controlled by a second loop consisting of nuclear hormone receptor REV-ERB α , which represses *Bmal1* expression, and retinoid-related orphan receptors (RORs) that drive *Bmal1* expression (Guillaumond et al., 2005; Preitner et al., 2002; Sato et al., 2004). CRY1 is a core clock repressor that, along with PER, determines circadian periodicity (Griffin et al., 1999; Kume et al., 1999), and degradation of PER and CRY affects period length. While mutations in casein kinase 1 ϵ lead to PER hyperphosphorylation and its proteasomal degradation, which shortens period (Meng et al., 2008), mutations in F box protein FBXL3 stabilize CRY1 by blocking its proteasomal degradation, which lengthens period (Busino et al., 2007; Godinho et al., 2007; Siepka et al., 2007). Ubiquitination of CRY1 by SCF (Skp1-Cul1-FBXL3) complex (Xing et al., 2013) and its proteasomal degradation regulate CRY1 stability. Recent studies indicate that the F box protein FBXL21 opposes the effect of FBXL3 on CRY1 degradation (Hirano et al., 2013; Yoo et al., 2013), suggesting that multiple mechanisms regulate turnover of CRY proteins. Whether macroautophagy (hereafter autophagy) degrades circadian proteins remains unknown.

In addition to serving as a clock repressor, CRY1 suppresses hepatic gluconeogenesis by regulating CREB/cAMP signaling, by rhythmic repression of glucocorticoid receptor, and by decreasing nuclear FoxO1 levels that downregulate gluconeogenic gene expression (Jang et al., 2016; Lamia et al., 2011; Zhang et al., 2010). Since the liver clock is regulated by nutrients, insulin, and glucagon, and since glucagon activates autophagy (Deter and De Duve, 1967), we considered the possibility that autophagy, regulation of liver clock, and glucose metabolism

Figure 1. BMAL1, CLOCK, REV-ERB α , and CRY1 Are Degraded by Lysosomes

(A) Scheme depicting use of lysosomal inhibitors (Lys Inh) intraperitoneally (i.p.) in mice at indicated time points.

(B–I) Immunoblots (IBs) and quantifications for net lysosomal flux of each indicated protein in livers at indicated time points in *ad libitum*-fed male mice injected with vehicle or Lys Inh as in (A); *n* = 4–8.

(J) Graph comparing relative rates of lysosomal degradation of each indicated circadian protein; *n* = 4–8.

(K) IB for indicated proteins in homogenate (Hom) and autophagosome (Aph) fractions from livers at 7 p.m. Two independent experiments are shown (*n* = 3 livers per Aph sample).

(L and M) Co-immunoprecipitation (coIP) of LC3 and IB for indicated proteins from livers at 7 p.m. (*n* = 7) and 3 p.m. (*n* = 3). Two independent coIP experiments are shown for 7 p.m. IgG, immunoglobulin G.

Values are mean $\pm$ SEM. In (C) and (D), **p* < 0.05, ***p* < 0.01, ****p* < 0.001; compare indicated values with the corresponding 7 p.m. value. One-way ANOVA and Bonferroni correction. Ponceau is the loading control. See also Figure S1.

and that CRY1 is degraded by autophagy in a temporal manner. We show that autophagic degradation of CRY1 releases its repression on gluconeogenesis and increases blood glucose levels. We unravel the mechanism of autophagic CRY1 degradation by identifying the specific LIR motifs on CRY1 that determine its interaction with LC3. Finally, we show that high-fat feeding decreases CRY1 protein levels in an autophagy-dependent

are interlinked. Autophagy degrades cytoplasmic contents in lysosomes (He and Klionsky, 2009). Induction of autophagy occurs by activation of class III PI3K complex and generation of PI3Ps, which recruit autophagy (ATG) proteins to cellular sites of autophagosome (Aph) formation (He and Klionsky, 2009). Activation of ATG7 initiates distinct conjugation cascades that lipidate cytosolic LC3-I into Aph-bound LC3-II (He and Klionsky, 2009). Aphs sequester cytoplasmic contents for degradation in lysosomes. Cargo sequestration requires interaction of their LC3-interacting region (LIR) motifs, which are W/F/Y-X-X-I/L/V sequences with LC3 (Birgisdottir et al., 2013). Analyses of CRY1 protein revealed several LIR motifs that formed the mechanistic basis to explore whether CRY1 interacts with LC3. Studies in *Atg7* knockout livers have revealed roles for autophagy in glycogen (Kern et al., 2016), glucose (Karsli-Uzunbas et al., 2014), and lipid metabolism (Singh et al., 2009); however, the mechanisms by which autophagy regulates glucose metabolism remain unclear. Since loss of hepatic *Atg7* via tail vein injections of adeno-associated viruses (AAVs) (*Atg7*^{KO}^{AAV-Cre}) led to hypoglycemia, we hypothesized that autophagy maintains gluconeogenesis and blood glucose levels by degrading CRY1. Here, we show that circadian proteins are lysosomal substrates,

manner, and that restoring hepatic CRY1 levels reverses obesity-associated hyperglycemia. Our studies reveal CRY1 LIR motifs as potential targets to control obesity-associated hyperglycemia.

RESULTS

Temporal Degradation of Core Circadian Proteins in Lysosomes

To determine if, and when during the circadian period, core circadian proteins are degraded by autophagy, we administered the lysosomal inhibitor leupeptin intraperitoneally in mice 2 hr prior to collection of livers at 7 a.m., 11 a.m., 3 p.m., 7 p.m., 11 p.m., and 3 a.m. (Figure 1A). Livers were homogenized and immunoblotted for LC3, clock inducers BMAL1 and CLOCK, and repressors PER1, PER2, CRY1, and REV-ERB α (Figures 1B and S1A). Accumulation of a protein at a given time point in the presence of leupeptin indicates its flux through lysosomes indicating degradation. Quantification of LC3-II flux (Figure 1C) revealed that induction of autophagy in livers from *ad libitum*-fed mice occurred between 3 p.m. and 11 p.m. with maximal activation at 7 p.m. Strikingly, lysosomal degradation of CRY1

(Figure 1D) also occurred between 3 p.m. and 11 p.m. and peaked at 7 p.m., coinciding with induction of autophagy. Immunoblotting of lysosome fractions from livers at each time point (as in Figure 1A) confirmed that CRY1 is indeed a lysosomal substrate that undergoes maximal degradation at 7 p.m. (Figure S1B). By contrast, analyses of PER1/2 flux excluded these proteins as lysosomal targets (Figures 1E and 1F). Interestingly, BMAL1, CLOCK, and REV-ERB α (Figures 1G–1I) each displayed greater net flux/degradation in lysosomes compared with CRY1 (comparisons of individual flux rates in Figure 1J); however, the temporal pattern of degradation of each of these proteins was distinct from that of LC3 and CRY1 (Figures 1C and 1D). For instance, lysosomal degradation of BMAL1 occurred at high rates between 7 a.m. and 3 p.m. and at 3 a.m. that were separated by decreased lysosomal degradation at 11 p.m. (Figure 1G). The lysosomal degradation of CLOCK occurred maximally at 11 a.m. and 3 a.m. with reduced turnover at 7 p.m. (Figure 1H). By contrast, lysosomal degradation of REV-ERB α increased gradually from 7 a.m. to 3 p.m. followed by a rapid decline in its degradation for the rest of the period (Figure 1I). Increases in circadian protein levels in leupeptin-treated samples were due to their accumulation in lysosomes and not from increased gene expression since equivalent expression of *Bmal1*, *Clock*, and *Cry1* genes was observed in livers from control and leupeptin-treated mice (Figures S1C–S1E). These results demonstrate that BMAL1, CLOCK, REV-ERB α , and CRY1 proteins are lysosomal substrates and exhibit distinct temporal patterns of lysosomal degradation (Figure 1J).

To validate that CRY1 is degraded in lysosomes in a temporal manner, we subjected livers harvested at 7 a.m. and 7 p.m. from *ad libitum*-fed mice to immunostaining for CRY1 and lysosomal marker LAMP1. Consistent with results from lysosomal flux analyses (Figure 1B), immunofluorescence (IF) revealed an increase in co-localization of CRY1 with LAMP1 at 7 p.m., but not at 7 a.m. (Figure S1F). We also noted a remarkable increase in LAMP1 signal in livers at 7 p.m. (Figure S1F), indicating expansion of lysosome-related acidic organelles at 7 p.m. compared with livers at 7 a.m., which we confirmed by demonstrating ~50% increase in *Lamp1* gene expression at 7 p.m. compared with 7 a.m. (Figure S1G). Lysosomal expansion likely contributed to induction of LC3-II/autophagy flux and CRY1 degradation at 7 p.m. (Figures 1C and 1D).

Since LC3 and CRY1 were degraded over a similar time course, we next explored whether degradation of CRY1 is LC3 dependent. Consequently, we first tested whether CRY1 is sequestered by APhs. APhs were isolated from liver by density gradient centrifugation (Marzella et al., 1982) and fractions were validated by their enrichment of APh marker LC3-II by immunoblotting (Figure 1K). Consistent with increased CRY1 flux at 7 p.m. (Figure 1D), APhs from 7 p.m. livers were enriched in CRY1, but not BMAL1/CLOCK (Figures 1G, 1H, and 1K), indicating that CRY1 is sequestered by APhs and thereby degraded by autophagy. Although lack of PER2 accumulation in the presence of leupeptin excludes it as an autophagy substrate (Figure 1F), PER2 co-purified with CRY1 in APhs at 7 p.m. (Figure 1K). Co-immunoprecipitation (coIP) analyses from livers at 7 p.m. confirmed that LC3 interacts with CRY1 and PER2, but not PER1, BMAL1, or CLOCK (Figure 1L). CoIP analyses at 3 p.m. revealed the interaction of CRY1

with LC3, but not PER2 (Figure 1M), supporting that CRY1 is degraded by autophagy.

Autophagy Degrades CRY1 in a Time-Dependent Manner

Three distinct mechanisms deliver cargo to lysosomes: macroautophagy (or autophagy) (He and Klionsky, 2009), chaperone-mediated autophagy (CMA) (Cuervo, 2010), and endosomal microautophagy (eMI) (Sahu et al., 2011). Loss of *Atg7* blocks APh formation and autophagy but has no effect on CMA (Park et al., 2015; Rodriguez-Muela et al., 2013) and eMI (Sahu et al., 2011). Since CRY1 was detected in APhs and interacted with LC3, we sought to confirm whether CRY1 is an autophagy substrate. Consequently, we depleted the autophagy gene *Atg7* in livers of *Atg7* floxed mice by tail vein injections of AAVs expressing *Cre* recombinase (hereafter *Atg7*KO) for 7 and 13 days. We intended to establish a model of short-term autophagy inhibition *in vivo* such that adverse effects of prolonged autophagy suppression are eliminated. Depleting *Atg7* in livers for 7 and 13 days each blocked autophagy, indicated by decreased ATG7 and LC3-II levels, although complete loss of ATG7 and accumulation of autophagy cargo p62 were observed after 13 days of *Cre* injections (Figure 2A). Importantly, loss of *Atg7* for 7 or 13 days each led to accumulation of CRY1, but not CRY2 (Figure 2A). In addition, accumulation of CRY1 in *Atg7*-deficient livers was detected in tissue homogenates and cytosol, and in nuclear fractions (validated by enrichment of nuclear marker Lamin A/C) where CRY1 translocates to repress BMAL1/CLOCK transcriptional activity (Figure 2B). Since the SCF complex ubiquitinates CRY1 for proteasomal degradation (Xing et al., 2013), and since autophagy degrades cargo “in bulk,” we explored whether SCF components that associate with CRY1 might also be degraded by autophagy at 7 p.m. Interestingly, APhs from livers of wild-type (WT) mice at 7 p.m. were enriched in SCF components Skp1 and FBXL3 (Figure S2A). Furthermore, *Atg7*-null livers displayed ~2-fold increase in CRY1, ~4-fold increase in Skp1, and ~30% increase in FBXL3 levels (Figure S2B), suggesting that autophagy degrades components of the SCF complex in addition to CRY1. Although lysosomal flux analyses showed decreased turnover of BMAL1 and CLOCK in *Atg7*KO livers (Figure S2C), BMAL1 and CLOCK did not interact with LC3, enrich in APhs (Figures 1K–1M), or accumulate in *Atg7*-deficient livers (Figure 2C), excluding them as macroautophagy targets. Dampened BMAL1/CLOCK flux in *Atg7*KO livers likely resulted from modest decreases in BMAL1/CLOCK protein levels (Figure 2C) secondary to decreased *Bmal1* and *Clock* gene expression (Figures 2J–2M).

Loss of Autophagy Disrupts the Circadian Clock in Liver

Since CRY1 is degraded by autophagy, we investigated the effect of loss of *Atg7* on oscillations of the liver clock across period. Deletion of *Atg7* resulted in loss of LC3-II and accumulation of LC3-I at each time point, indicating loss of autophagy (Figures 2C and 2D). As anticipated, loss of autophagy resulted in accumulation of CRY1 at each time point; however, no increases in CRY2 protein levels were noted (Figures 2C, 2E, and S2D). Increased CRY1 protein levels block BMAL1/CLOCK transcriptional activity, leading to repression of *Cry1* gene; hence,

Figure 2. Autophagy Specifically Degrades CRY1 and Regulates the Liver Clock

(A and B) IB for indicated proteins in livers from *Atg7^{fllox/flox}* mice subjected to tail vein injections of control (Con) and *Cre*-expressing AAVs for 7 or 13 days, and liver homogenates (Hom), cytosol (Cyt), and nuclear (Nuc) fractions from mice injected with *Cre*-expressing AAVs for 13 days; *n* = 6. Quantification for (B) is shown.

(C–O) (C–E, G, I, J, L, and N) IB and quantification for indicated proteins in blots in (C), and (F, H, K, M, and O) RT-PCR for corresponding circadian genes from livers harvested at six indicated time points across 24 hr from *ad libitum*-fed male mice injected with Con or *Cre*-expressing AAVs (*Atg7KO*) for 13 days; *n* = 5–7.

Values are mean $\pm$ SEM. **p* < 0.05, ***p* < 0.01, ****p* < 0.001; compare values in *Atg7KO* mice with corresponding values in Con mice. Student's *t* test or two-way ANOVA and Bonferroni correction. Ponceau is the loading control. See also Figure S2.

Loss of Autophagy Affects Nuclear and Cytoplasmic Levels of Core Circadian Proteins

Nucleocytoplasmic shuttling of circadian proteins and degradation of PER/CRY each modulate period length. Because blocking autophagy resulted in accumulation of CRY1 and decreases in levels of BMAL1, CLOCK, and REV-ERB α , we characterized in greater detail the effect of loss of autophagy on period-wide oscillations of these proteins in nuclear and cytoplasmic compartments. To that purpose, livers were harvested at 7 a.m., 11 a.m., 3 p.m., 7 p.m., 11 p.m., and 3 a.m. from control and *Atg7*-deficient livers (13 days after a single AAV-*Cre* injection),

abundance of CRY1 in *Atg7*-deficient livers should, in principle, dampen *Cry1* expression. Indeed, *Atg7*-deficient livers showed significantly decreased *Cry1* expression across period (Figure 2F), suggesting a functional increase in CRY1-driven repression of BMAL1/CLOCK activity. *Atg7*-deficient livers displayed a reduction in PER1 protein levels that could not be explained by changes in *Per1* expression, while PER2 protein levels remained largely unaffected (Figures 2G–2I). *Atg7*-deficient livers also displayed decreased BMAL1 protein levels and *Bmal1* gene expression (Figures 2J and 2K) and modestly reduced CLOCK levels at 3 p.m. that were associated with decreased *Clock* expression (Figures 2L and 2M). Levels of REV-ERB α protein (Figure 2N) and *Rev-erba* and *Rev-erbb* gene expression were also suppressed in *Atg7*-deficient livers (Figures 2O and S2E), reflecting an overall trend toward dampening of the oscillations of the liver clock in absence of autophagy. Reduction of *Bmal1* expression in *Atg7KO* livers likely occurred due to decreased expression of *Rora* (Figure S2F), which encodes for ROR α , which drives *Bmal1* gene expression (Guillaumond et al., 2005; Sato et al., 2004). In sum, these results indicate that loss of autophagy disrupts the liver clock.

following which nuclear and cytosolic fractions were generated. Autophagy deficiency was verified by accumulation of LC3-I in both nuclear and cytosolic fractions from *Atg7KO* mice (Figures 3A–3C), while nuclear enrichment was confirmed by abundance of nuclear marker Lamin A/C and its absence in cytosolic fractions (Figure S3A). As expected, biochemical fractionation and IF revealed ~2- to 3-fold increase in CRY1 accumulation in nucleus in livers from *Atg7KO* mice (Figures 3A, 3D, and 3E). Although both nuclear and cytosolic fractions from *Atg7KO* mice showed increased CRY1 accumulation (Figures 3A–3E), greater retention of CRY1 was observed in the nucleus than cytoplasm (Figure 3D). These findings are consistent with the fact that CRY1 exerts its repressive function by nuclear translocation. We next explored the effect of loss of autophagy on oscillations of additional core circadian proteins in nuclear and cytoplasmic compartments. Consistent with decreased BMAL1/CLOCK protein levels in homogenates (Figures 2J and 2L), BMAL1 and CLOCK levels were also decreased in nuclear fractions from *Atg7KO* livers compared with controls (Figures 3F and 3G). Modest reduction in BMAL1 protein was also detected in cytoplasm from *Atg7KO* livers at 7 a.m. (Figure 3F),

Figure 3. Loss of Autophagy Affects Nuclear Levels of Core Circadian Proteins

(A–D and F–H) IB for nuclear and cytosolic distribution of indicated circadian proteins, autophagy-related protein LC3, FBXL3, Skp1, and FBXL21 in livers across 24 hr from *ad libitum*-fed male mice injected with Con or Cre-expressing AAVs (*Atg7KO*) for 13 days; $n = 4$ –8. Quantifications for nuclear and cytosolic distribution of LC3, CRY1, BMAL1, CLOCK, and FBXL3 are depicted. Quantifications for nuclear and cytosolic distribution of PER1, PER2, REV-ERB α , Skp1, and FBXL21 are shown in Figure S3.

(E) Indirect IF for CRY1 (green) in livers and quantification for nuclear and total cellular CRY1 content at 7 p.m. in livers from *ad libitum*-fed male mice injected with Con or Cre-expressing AAVs (*Atg7KO*) for 13 days; $n = 4$. Scale bar, 10 μ m.

Values are mean $\pm$ SEM. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$; compare values in *Atg7KO* mice with corresponding values in Con mice. Student's *t* test or two-way ANOVA and Bonferroni correction. Ponceau is the loading control. See also Figure S3.

although the significance of this finding remains unclear. Consistent with our observations in total homogenates, nuclear and cytoplasmic levels of PER1 and REV-ERB α were also significantly reduced across period in *Atg7KO* livers, while no changes

in PER2 levels were detected (Figures S3B–S3D). Taken together, these findings reflect a remarkable dampening in the oscillations of core circadian genes, a hallmark of age-associated changes in rhythmicity (Cornelissen and Otsuka, 2017;

Zwighaft et al., 2015). Given that autophagy decreases with age (Rubinsztein et al., 2011), our data suggest that defects in autophagy may contribute to the recently elucidated effects of aging on the molecular clock.

Because loss of *Atg7* led to accumulation of CRY1 and SCF complex (FBXL3 and Skp1) (Figure S2B), which facilitates ubiquitination/degradation of CRY1 (Xing et al., 2013), we next characterized the effect of loss of autophagy on period-wide changes in nuclear and cytoplasmic levels of FBXL3 and Skp1. Interestingly, loss of autophagy led to accumulation of FBXL3 and Skp1 in the nucleus across the period, although increases in both molecules occurred most significantly at 3 a.m. (Figures 3H and S3E). FBXL3 did not accumulate in cytosolic fractions; however, a significant increase in cytosolic Skp1 accumulation was noted in *Atg7*KO livers at 3 a.m. (Figure S3E). While the mechanism of sequestration of nuclear FBXL3 by autophagy is unclear, given the enrichment of CRY1, FBXL3, and Skp1 in APhs, our results suggest that CRY1 and SCF are likely degraded by autophagy as a complex. Since cytoplasmic FBXL21, another member of the F-box-type E3 ubiquitin ligase family (Jin et al., 2004), opposes the function of FBXL3 and promotes CRY1 stability (Hirano et al., 2013; Yoo et al., 2013), we tested whether loss of autophagy led to accumulation of FBXL21, which, in turn, increased CRY1 stability/levels in *Atg7*KO livers. Loss of autophagy did not affect FBXL21 protein levels (Figure S3F), excluding the possibility that accumulation of CRY1 in *Atg7*KO livers occurred from an FBXL21-dependent increase in CRY1 stability.

Autophagic Degradation of CRY1 Sustains Gluconeogenesis

Since depleting *ATG7* in livers increases CRY1 levels, and since CRY1 suppresses gluconeogenesis (Jang et al., 2016; Lamia et al., 2011; Zhang et al., 2010), we hypothesized that autophagic degradation of CRY1 maintains blood glucose levels by driving gluconeogenesis. Consistent with previous work showing a role for autophagy in preventing hypoglycemia (Karsli-Uzunbas et al., 2014), *Atg7* floxed mice displayed significant reduction in blood glucose levels when tested at 7 p.m. as early as 3 days after *Cre* injections (Figure 4A). After a week of *Cre* injections, *Atg7*KO mice showed lower blood glucose at each time point across the circadian period, demonstrating that hepatic autophagy is required to maintain blood glucose levels (Figure 4B). Reduced blood glucose levels did not occur from decreased glycogen breakdown by autophagy since acute loss of *Atg7* in livers associated with diminished hepatic glycogen stores across the period (Figure S4A). In fact, livers from *Atg7*KO mice were largely depleted of glycogen compared with controls, indicating significant deficiency in glucose production/storage in liver. Although *Atg7*KO mice consumed less food in the nocturnal cycle, both control and *Atg7*KO mice consumed equal amounts of food in the diurnal cycle, excluding differences in diurnal feeding as the reason for reduced blood glucose levels (Figure S4B).

Mice rely on gluconeogenesis to maintain diurnal blood glucose levels since they consume a significant proportion of their total calories in the early hours of the dark cycle. To begin to test whether lower blood glucose levels in *Atg7*KO mice occurred from decreased gluconeogenesis, we first characterized the temporal changes in expression of gluconeogenic genes in normal

mice across the circadian period. While livers from *ad libitum*-fed control mice showed progressive increases (~2-fold) in expression of gluconeogenic genes *G6p*, *Pck1*, and *Pc* between 3 p.m. and 7 p.m., *Atg7*-deficient livers failed to induce these genes at similar time points (Figures 4C–4E). *Atg7*KO mice were also unable to increase their blood glucose levels when subjected to pyruvate tolerance tests (PTTs) at 6 p.m., indicating impaired gluconeogenesis (Figure 4F). The transcription factor FoxO1 translocates to the nucleus and drives gluconeogenesis during reduced feeding when insulin levels are low (Puigserver et al., 2003), and because CRY1 participates in the degradation of nuclear FoxO1 (Jang et al., 2016), we tested whether decreased gluconeogenesis in *Atg7*KO mice is associated with reduced nuclear FoxO1 content. Indeed, *Atg7*KO livers displayed a significant reduction in nuclear FoxO1 levels compared with controls (Figures 4G and 4H), while cytoplasmic FoxO1 levels remained largely unaffected (data not shown). Reduction in nuclear FoxO1 levels did not occur from its retention in the cytoplasm since circulating levels of insulin, a factor that drives FoxO1 phosphorylation and cytoplasmic retention, were largely reduced in *Atg7*KO mice (Figure S4C). Given the accumulation of CRY1 in *Atg7*KO livers (Figures 3A, 3D, and 3E), it is likely that reduction in nuclear FoxO1 results from CRY1-mediated degradation of FoxO1, as shown recently (Jang et al., 2016). Decreased gluconeogenesis in *Atg7*KO mice could not be explained by changes in nuclear levels of phosphorylated CREB, which is known to activate gluconeogenesis (Koo et al., 2005). In fact, nuclear levels of phosphorylated CREB were elevated from 7 p.m. to 11 p.m. in *Atg7*KO livers (Figure 4I) and circulating glucagon (Figure S4D), which phosphorylates CREB and drives gluconeogenesis (Koo et al., 2005), was also significantly elevated in *Atg7*KO livers (Figures 4G, 4I, and 4J). In sum, decreased gluconeogenesis in *Atg7*KO livers correlated with reduced nuclear FoxO1 levels, which suggests that FoxO1 plays a key role in aberrant glucose homeostasis in these animals, while induction of glucagon/CREB signaling in *Atg7*KO mice is a compensatory attempt to unsuccessfully restore blood glucose levels.

More importantly, to determine whether suppression of gluconeogenesis in *Atg7*KO mice occurs from increased CRY1 levels, we tested whether dampening CRY1 levels in *Atg7*-deficient livers (by injecting small hairpin RNAs [shRNAs] against CRY1) (Figure 4K) prevents the reduction in blood glucose levels. While reducing *Cry1* expression by ~80% (Figure S4E) and CRY1 protein levels by ~50% (Figure S4F) failed to affect blood glucose levels in control mice (Figure 4L), dampening *Cry1* expression in *Atg7*KO livers increased blood glucose levels from 75 ± 2 to 102 ± 4 mg/dL at 7 p.m. ($p < 0.001$) (Figure 4L). Increases in blood glucose levels in *Atg7*KO mice after depletion of CRY1 occurred specifically between 3 p.m. and 9 p.m., which coincides with the circadian interval when autophagy maximally degrades CRY1 (Figures 1C and 1D). These data show that degradation of CRY1 by autophagy occurs during the day when mice consume less food, and that autophagic degradation of CRY1 sustains blood glucose levels.

Identifying CRY1 LIR Motifs that Regulate Its Degradation by Autophagy

To determine the mechanism of degradation of CRY1 by autophagy, we first examined for presence of canonical LIR motif

Figure 4. Autophagic Degradation of CRY1 in Liver Controls Gluconeogenesis

(A) Blood glucose levels at 7 p.m. on indicated days after *Atg7^{flx/flx}* male mice were injected with control (Con) or *Cre*-expressing AAVs (*Atg7KO*); *n* = 4. (B–F) Blood glucose levels (*n* = 6–12) and expression of gluconeogenic genes *G6p*, *Pck1*, and *Pc* in liver, and intraperitoneal PTT from male mice at indicated time points across 24 hr on day 7 after injections of Con or AAV-*Cre*; *n* = 4. (G–J) IB for indicated proteins in the nucleus in livers at indicated time points across 24 hr from Con and *Atg7KO* male mice. Quantifications for nuclear levels of indicated proteins are shown; *n* = 4–5. (K and L) Experimental plan showing assessment of blood glucose levels at indicated time points on day 7 after Con and AAV-*Cre* injections (i.e., 1 day after tail vein injections of AAVs expressing Con or shCRY1 constructs on day 6); *n* = 3–10. Graph depicts blood glucose values at 7 p.m.; *n* = 10. Values are mean ± SEM. **p* < 0.05, ***p* < 0.01, ****p* < 0.001; n.s., not significant; compare values in *Atg7KO* mice with corresponding values in Con mice. ###*p* < 0.001; compare indicated values in Con mice with 7 a.m. values in Con mice. Student's *t* test or one-way or two-way ANOVA and Bonferroni correction. Ponceau is the loading control. See also Figure S4.

Figure 5. LIR Motifs Determine CRY1 Degradation and Regulation of Gluconeogenesis

(A) Murine CRY1 has 13 LIR motifs (green).
 (B) Inactivation of selected LIR motifs (mLIR1-4) on CRY1 via mutagenesis of tyrosine (Y), valine (V), or leucine (L) residues (green) to alanine (A) (red).
 (C) IB for FLAG in livers from male mice at 7 p.m. expressing FLAG-tagged WT-CRY1 plasmid or each FLAG-tagged CRY1 LIR mutant plasmid (mLIR1-4); n = 12.
 (D) IB for LC3 in livers from male mice at 7 p.m. expressing FLAG-tagged WT-CRY1 or each CRY1 LIR mutant (mLIR1-4) and cultured in presence or absence of Lys Inh for 2 hr; n = 7-10.
 (E and F) IB for BMAL1 and G6P in livers from male mice at 7 p.m. expressing FLAG-tagged WT-CRY1 plasmid or each CRY1 LIR mutant plasmid (mLIR1-4); n = 8-12.

(legend continued on next page)

W/F/Y-X-X-I/L/V sequences in CRY1 (Birgisdottir et al., 2013). We identified 13 putative LIRs on CRY1 (Figure 5A), which were prioritized for mutagenesis based on their accessibility determined by visualization of crystal structure of mouse CRY1 (PDB: 5T5X) (Michael et al., 2017) using the Swiss-PdbViewer software (<http://www.expasy.org/spdbv/>) (Guex and Peitsch, 1997), and on presence of negatively charged residues in the vicinity of LIR motifs that facilitate binding to LC3 (Birgisdottir et al., 2013). This revealed four LIR motifs on CRY1 as candidates for interaction with LC3, which were individually inactivated in FLAG-tagged CRY1 plasmid by mutating their tyrosine, valine, or leucine residues to alanine (Figure 5B). We then determined the role of each LIR motif in degradation of CRY1 by expressing FLAG-tagged WT-CRY1 plasmid and each CRY1 mutant LIR plasmid (mLIR1, mLIR2, mLIR3, and mLIR4 as in Figure 5B) in liver via tail vein injections using the *jet-PEI* *in vivo* transfection system (Chang et al., 2014) (Figure S5A). We also explored whether blocking autophagic degradation of CRY1 by inactivating its LIRs affects gluconeogenesis. Prior to injecting mice with mLIR CRY1 plasmids, we tested the robustness of the experimental system by determining the degree to which expression of FLAG-tagged WT-CRY1 suppresses hepatic gluconeogenesis compared with empty vector. As reported in cultured hepatocytes (Jang et al., 2016), expressing WT-CRY1 in livers (Figure S5B) decreased the expression of gluconeogenic genes *Pck1* and *G6p* by ~80%–90% (Figure S5C) and lowered blood glucose levels by 50% (~50 mg/dL) at 7 p.m. (Figure S5D). We then titrated the dose of injected WT-CRY1 plasmid such that blood glucose levels were consistently maintained at ~80–90 mg/dL between 1 p.m. and 7 p.m. Consistent with the idea that inactivating LIR motifs on CRY1 prevents its degradation, expressing each of the four FLAG-tagged mLIR CRY1 in liver led to varying degrees of accumulation of FLAG compared with WT-CRY1 (Figure 5C). Strikingly, mLIR1-CRY1 and mLIR4-CRY1 accumulated significantly more than mLIR2-CRY1 and mLIR3-CRY1 or WT-CRY1. Levels of mLIR2 and mLIR3 CRY1 were moderately higher than WT-CRY1, but differences between these groups remained statistically insignificant (Figure 5C). These results indicate that LIR1 (²⁷¹DLYKKV²⁷⁶) and LIR4 (⁴⁹²SRYRGL⁴⁹⁷) are required for degradation of CRY1 by autophagy. Accumulation of mLIR1-CRY1 and mLIR4-CRY1 did not occur from reduced autophagy per se, indicated by equivalent LC3-II flux in livers injected with WT or mLIR-CRY1 plasmids (Figure 5D), or from changes in transfection determined by qPCR showing equivalent *Cry1* expression in livers injected with WT and mLIR-CRY1 plasmids (Figure S5E). CoIP in 293T cells confirmed that interactions of mLIR1-CRY1 and mLIR4-CRY1 with GFP-tagged LC3 were remarkably reduced compared with WT-CRY1, mLIR2-CRY1, or mLIR3-CRY1 (Figure S5F). These results are consistent with significant accumulation of mLIR1-CRY1 and mLIR4-CRY1 and moderate accumulation of mLIR2 and mLIR3 CRY1 in liver compared with WT-CRY1 (Figure 5C). Consistent with our observation

that accumulation of CRY1 in *Atg7*KO mice associates with decreased BMAL1 levels (Figure 2J), accumulation of mLIR1-CRY1 or mLIR4-CRY1 each associated with reduced BMAL1 levels (Figure 5E), indicating that expressing autophagy-resistant forms of CRY1 is sufficient to disrupt the liver clock.

LIR Motifs Link CRY1 Degradation to Regulation of Gluconeogenesis

Since increases in hepatocellular CRY1 protein inhibit gluconeogenesis, we next tested whether accumulation of mLIR1-CRY1 or mLIR4-CRY1 was sufficient to suppress hepatic glucose production/blood glucose levels. Indeed, mice injected with mLIR1-CRY1 or mLIR4-CRY1, but not mLIR2-CRY1 and mLIR3-CRY1 constructs, displayed reduced G6P protein levels (Figure 5F) and decreased blood glucose levels at 7 p.m. (Figures 5G–5J). Furthermore, mLIR1-CRY1- or mLIR4-CRY1-injected mice, and not the mLIR2-CRY1- and mLIR3-CRY1-injected mice, exhibited less glucose production when subjected to PTTs (Figure 5K), indicating that LIR motifs ²⁷¹DLYKKV²⁷⁶ and ⁴⁹²SRYRGL⁴⁹⁷ link CRY1 turnover by autophagy to regulation of gluconeogenesis. Most surprisingly, CRY1 LIR2 (²⁸⁵SLYGQL²⁹⁰) and LIR4 (⁴⁹²SRYRGL⁴⁹⁷) are also required for degradation of SCF components Skp1 and FBXL3 by autophagy, since livers injected with mLIR2-CRY1, mLIR3-CRY1, and mLIR4-CRY1 each showed accumulation of these proteins compared with WT-CRY1 or mLIR1-CRY1 (Figure S5G). These data suggest that SCF components Skp1 and Fbxl3 are likely targeted for autophagic degradation via their association with CRY1 (Xing et al., 2013), which, in turn, binds to LC3 via its LIR motifs.

High-Fat-Diet Feeding Decreases CRY1 Protein Levels in Liver

Because obesity dysregulates gluconeogenesis and given our finding that autophagic turnover of CRY1 derepresses hepatic gluconeogenesis under physiological states, we hypothesized that obesity accelerates the degradation of CRY1 by autophagy, which increases glucose production. To test this hypothesis, C57BL/6J male mice were fed a regular chow diet (RD) or high-fat diet (HFD; 60% calories in fat) for 8 weeks, following which livers were collected at 7 a.m., 11 a.m., 3 p.m., 7 p.m., 11 p.m., and 3 a.m. and assessed for period-wide changes in (1) expression of gluconeogenic genes and (2) levels of core circadian proteins and the autophagy protein LC3. As expected, HFD feeding for 8 weeks significantly increased expression of gluconeogenic genes *G6p*, *Pck1*, *Fbp1*, and *Pc* in liver (Figures S6A–S6D). Although we noted qualitative differences in the patterns of their expression across period, a unifying feature was maximal induction of gluconeogenic genes at 7 p.m. Consequently, we tested whether increased gluconeogenic gene expression at 7 p.m. correlated with decreased CRY1 protein levels in nuclear and cytoplasmic compartments from livers of HFD-fed mice. Indeed, period-wide assessments in livers revealed that HFD feeding progressively decreased nuclear and

(G–K) Blood glucose levels at indicated time points ($n = 9$ –16) and intraperitoneal PTT at 6 p.m. from male mice expressing FLAG-tagged WT-CRY1 plasmid or each CRY1 LIR mutant plasmid in liver; $n = 5$. AUC, area under the curve.

(L) Cartoon summarizing temporal autophagic degradation of CRY1 and its effects on gluconeogenesis and blood glucose levels.

Values are mean $\pm$ SEM. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$. Student's *t* test, one-way or two-way ANOVA and Bonferroni correction. Ponceau is the loading control. See also Figure S5.

Figure 6. High-Fat Feeding Decreases CRY1 Protein Levels in Liver

(A–K) IBs and quantifications for indicated proteins in nuclear and cytosolic fractions from livers at indicated time points from male mice fed regular chow diet (RD) or high-fat diet (HFD; 60% calories in fat) for 8 weeks. $n = 4-8$.

Values are mean $\pm$ SEM. * $p < 0.05$. ** $p < 0.01$. Two-way ANOVA and Bonferroni correction. Ponceau is the loading control. See also Figure S6.

cytosolic CRY1 levels (Figures 6A, 6B, and 6D) that were associated with increased levels of the autophagosome marker LC3-II in both nuclear and cytosolic fractions (Figures 6A–6C). Reduction in CRY1 levels did not occur from changes in expression

of repressor genes *Cry1* or *Per1* (Figures S6E and S6F). Indeed, while HFD feeding moderately decreased *Cry1* gene expression at 3 a.m. and 7 a.m., no differences were observed between RD- and HFD-fed mice from 11 a.m. to 11 p.m., the broad

interval when CRY1 regulates gluconeogenesis (Figure S6E). These data suggest that early obesity, as observed with 8 weeks of HFD feeding, is sufficient to promote CRY1 protein instability.

HFD feeding did not have a remarkable effect on levels of the other core circadian proteins (Figure 6), although we did note an interesting trend toward slight increases in nuclear levels of PER1, PER2, and REV-ERB α and reduction in their corresponding levels in the cytosol (Figures 6E, 6F, and 6I). Nuclear and cytosolic levels of BMAL1 were modestly decreased in the early hours of the light cycle, which correlated with decreased *Bmal1* gene expression in livers from HFD-fed mice (Figures 6G and S6G), as shown previously (Eckel-Mahan et al., 2013). Conversely, modest increases in cytosolic CLOCK protein after 3 p.m. correlated with increased *Clock* gene expression (Figures 6H and S6H). HFD feeding modestly increased cytoplasmic FBXL3 and nuclear FBXL21 levels and did not affect levels of Skp1 (data not shown); however, these changes do not explain the instability of CRY1 in HFD-fed mice (Figures 6J and 6K). Taken together, these data show that moderate duration of HFD feeding is sufficient to decrease CRY1 protein levels in liver, forming the basis to explore whether decreases in CRY1 through autophagic degradation promote gluconeogenesis during early obesity.

Obesity Promotes Degradation of CRY1 in an Autophagy-Dependent Manner

Given these results, we asked whether HFD-feeding-induced CRY1 degradation is autophagy dependent. To that purpose, we subjected liver lysates from RD- and HFD-fed control and *Atg7*KO mice to immunoblotting for CRY1, while CLOCK served as a control. While *Atg7* loss in RD- or HFD-fed mice (Figure S7A) did not affect CLOCK protein levels at 7 p.m. (Figures 7A and 2L), loss of *Atg7* (as early as 7 days after AAV-Cre injection) blocked the degradation of CRY1 in livers from HFD-fed mice by ~50% (Figure 7A), demonstrating that autophagy contributes to CRY1 instability in HFD-fed mice (Figure 6D).

Restoring CRY1 Levels Prevents Obesity-Associated Dysregulation of Gluconeogenesis

To mechanistically link autophagic degradation of CRY1 to increased hepatic gluconeogenesis in obese mice, we tested whether two distinct approaches to reconstitute hepatic CRY1 levels in obese mice will normalize glucose metabolism. Consequently, RD-fed C57BL/6J mice were subjected to PTT on day 1 prior to initiating them on HFD (60% calories in fat) for 8 weeks (plan in Figure S7B). After 7 weeks of HFD feeding, mice were subjected to a second PTT and then rested for 7 days, following which mice were tail-vein-injected with cDNA expressing WT-CRY1 and administered a PTT the next day (Figure S7B). Restoring CRY1 levels (~5-fold increase in *Cry1* expression in liver) (Figure S7C) was sufficient to lower blood glucose levels by ~50% in HFD-fed mice (Figure 7B), which associated with remarkable inhibition in expression of *Pck1*, *G6p*, and *Fbp1* (Figures S7D–S7F) and normalization of glucose production in a PTT compared with HFD-fed controls (Figure 7C). In addition, knocking out *Atg7* in 8-week HFD-fed mice (Figure 7D) increased hepatic CRY1 levels by ~50% (Figure 7A), reduced glucose production in a PTT (Figure 7E), and decreased the expression of *Fbp1*, *G6p*, *Pc*, and *Pck1* compared with HFD-fed controls (Figures 7F–7I). Normalization of glucose homeostasis in

HFD-fed *Atg7*KO mice occurred due to accumulation of CRY1 (Figure 7A) and not due to differences in *Cry1* gene expression (Figure 7J). These results demonstrate that inhibiting autophagy in liver or targeting specific LIR motifs on CRY1 to prevent their autophagic degradation is sufficient to normalize obesity-associated dysregulation of gluconeogenesis, revealing LIRs on CRY1 as therapeutic targets against hyperglycemia.

DISCUSSION

In this study, we show that autophagy in the liver degrades CRY1 during a temporal window when rodents typically eat less and subsist on gluconeogenesis. The enrichment of CRY1 in APhs, its interaction with LC3, and accumulation of CRY1 in autophagy-deficient livers demonstrate that CRY1 is an autophagy substrate. Site-directed mutagenesis to inactivate distinct LIR motifs on CRY1 reveals two LIRs that regulate CRY1 degradation by autophagy. Degradation of CRY1 allows induction of gluconeogenesis and maintenance of blood glucose levels. Consistent with this notion, mice with *Atg7*-deficient livers display increased CRY1 levels and reduced blood glucose levels, which are rescued in part by decreasing their hepatic CRY1 content. Rescue of blood glucose occurs selectively between 3 p.m. and 7 p.m., suggesting that autophagic CRY1 degradation is time imprinted to a specific physiological function: maintenance of blood glucose levels during reduced feeding. A well-defined signaling module that induces autophagy during nutrient depletion is AMPK, and phosphorylation by AMPK promotes CRY1 degradation (Lamia et al., 2009). Although AMPK primes CRY1 for proteasomal degradation, whether phosphorylation by AMPK facilitates CRY1 sequestration by autophagy remains unknown. It is thought that phosphorylation of residues in proximity to LIR motifs facilitates LIR-LC3 interaction (Birgisdottir et al., 2013). Examination of CRY1 protein revealed that serine 280, a residue phosphorylated by AMPK, lies distal to LIR ²⁷¹DLYKKV²⁷⁶. We have found that inactivating ²⁷¹DLYKKV²⁷⁶ led to CRY1 accumulation. It is thus possible that introducing a negative charge in the vicinity of CRY1 LIR could increase its degradation via autophagy, and from that perspective, serine 280 phosphorylation could drive CRY1 degradation by autophagy. Whether such cooperativity determines the fate of CRY1 protein remains to be seen. We were intrigued by the finding that PER2 and CRY1 each interact with LC3 at 7 p.m. when CRY1 is maximally degraded by autophagy, yet PER2 does not accumulate in autophagy-deficient livers. We speculate that PER2, a known interacting partner of CRY1, is a cargo adapter that facilitates interaction of CRY1 with LC3, although future studies will be required to test this notion. We were also intrigued by the finding that SCF components Skp1 and Fbxl3, which determine CRY1 degradation by the proteasome, are also autophagy substrates. In the context of this study, it would seem that reduced feeding at specific diurnal intervals directs hepatocytes to prioritize autophagic degradation of CRY1 and possibly CRY1-associated proteins (e.g., Skp1 and Fbxl3), such that suppressive effects of CRY1 on gluconeogenesis are effectively neutralized. Loss of autophagy resulted in pronounced accumulation of FBXL3 and Skp1 in the nucleus, which begs further investigation on mechanisms of sequestration of these nuclear-localized proteins by

Figure 7. Restoring CRY1 Prevents Obesity-Associated Dysregulation of Gluconeogenesis

(A) IB for CRY1 and CLOCK in livers from male mice fed RD or HFD for 8 weeks. Then subsets of mice were injected with control (Con) or Cre-expressing AAVs (Atg7KO), as in (D); n = 5. KO, knockout.

(B and C) Blood glucose and PTT at indicated time points in male mice fed HFD for indicated PTT duration (plan in Figure S7B), following which a subset of mice was injected with WT-CRY1 for 1 day; n = 5–8.

(D and E) Experimental plan and PTT at indicated time points (before HFD feeding, 7 weeks after HFD feeding, and 1 week after AAV-Cre injection) in male mice fed RD or HFD for 7 weeks. Then subsets of mice were injected with Con or Cre-expressing AAVs (Atg7KO); n = 5–10.

(F–J) RT-PCR for indicated genes in livers at 7 p.m. as per plan in (D); n = 4–8.

Values are mean $\pm$ SEM. *p < 0.05, **p < 0.01, ***p < 0.001. Student's t test or two-way ANOVA and Bonferroni correction. Ponceau is the loading control. See also Figure S7.

autophagy; however, these extensive cell biological excursions are beyond the scope of the present work. Taken together, we show that temporal degradation of CRY1 by autophagy derepresses hepatic gluconeogenesis, and that LIR motifs mechanistically link degradation of CRY1 to regulation of gluconeogenesis, revealing LIRs as potential targets for glycemic control.

Limitations of Study

We find that HFD feeding accelerates the degradation of CRY1 by autophagy, which is surprising given that chronic lipid stim-

ulus is thought to suppress autophagy (Singh et al., 2009). This is an exciting finding that begs the question of how CRY1 degradation is accelerated when autophagy is suppressed. These results allow us to consider the possibility that, despite the inhibitory effect of obesity on autophagy, chronic lipid availability may trigger post-translational modifications on autophagic cargo (e.g., phosphorylations in the vicinity of LIR motifs) that could make a subset of proteins more efficiently recognized by the residual autophagic machinery. The second limitation of our study is the lack of experiments that reveal the relative contribution of

the proteasome and autophagy to the degradation of CRY1. It could be possible that autophagy and the proteasome each regulate CRY1 levels at distinct intervals across period and likely respond to different environmental cues. Future studies will be required to address these limitations.

STAR★METHODS

Detailed methods are provided in the online version of this paper and include the following:

- KEY RESOURCES TABLE
- CONTACT FOR REAGENT AND RESOURCE SHARING
- EXPERIMENTAL MODEL AND SUBJECT DETAILS
 - Animals
 - Housing
- METHOD DETAILS
 - Autophagy Flux Assay
 - Isolation of Autophagic Structures and Nuclear Fractions
 - RNA Isolation and qPCR Analyses
 - Plasmids and Adeno-Associated Virus (AAV) Injections *In Vivo*
 - Plasmid Transfections *In Vitro*
 - Pyruvate Tolerance Test (PTT)
 - Western Blotting
 - Indirect Immunofluorescence
 - Assessments of Circadian Feeding Patterns
 - Biochemical Analyses
- QUANTIFICATION AND STATISTICAL ANALYSIS

SUPPLEMENTAL INFORMATION

Supplemental Information includes seven figures and one table and can be found with this article online at <https://doi.org/10.1016/j.cmet.2018.05.023>.

ACKNOWLEDGMENTS

We thank Drs. M. Komatsu and K. Tanaka (Tokyo Metropolitan Institute of Medical Science, Japan) for *Atg7^{F/F}* mice. This work was supported by R01 AG043517 (R.S.), P30 DK020541 (Einstein-Mount Sinai Diabetes Research Center), P01 AG031782 (project leader, R.S.), American Diabetes Association (ADA) postdoctoral fellowship #1-17-PMF-011 (M.T.), and ADA grant 1-18-IBS-062 (R.S.). E.M. is supported by R01 GM120358, and A.B.-G. is supported by T32 AG023475. We thank Dr. J. Bass (Northwestern University Feinberg School of Medicine) for his thought-provoking suggestions.

AUTHOR CONTRIBUTIONS

Conceptualization, R.S.; Methodology, M.T.; Investigation, M.T., A.B.-G., E.M., M.L.A., E.T., D.F., and J.S.; Writing – Original Draft, R.S.; Writing – Review & Editing, M.T. and R.S.; Funding Acquisition, R.S., M.T., and J.E.P.; Resources, P.M., F.B., G.J.S., and J.E.P.; Supervision, R.S.

DECLARATION OF INTERESTS

The authors declare no competing interests.

Received: September 13, 2017

Revised: March 19, 2018

Accepted: May 24, 2018

Published: June 21, 2018

REFERENCES

- Bass, J., and Takahashi, J.S. (2010). Circadian integration of metabolism and energetics. *Science* 330, 1349–1354.
- Birgisdottir, A.B., Lamark, T., and Johansen, T. (2013). The LIR motif - crucial for selective autophagy. *J. Cell Sci.* 126, 3237–3247.
- Busino, L., Bassermann, F., Maiolica, A., Lee, C., Nolan, P.M., Godinho, S.I., Draetta, G.F., and Pagano, M. (2007). SCFFbxl3 controls the oscillation of the circadian clock by directing the degradation of cryptochrome proteins. *Science* 316, 900–904.
- Chang, R.M., Yang, H., Fang, F., Xu, J.F., and Yang, L.Y. (2014). MicroRNA-331-3p promotes proliferation and metastasis of hepatocellular carcinoma by targeting PH domain and leucine-rich repeat protein phosphatase. *Hepatology* 60, 1251–1263.
- Cornelissen, G., and Otsuka, K. (2017). Chronobiology of aging: a mini-review. *Gerontology* 63, 118–128.
- Cuervo, A.M. (2010). Chaperone-mediated autophagy: selectivity pays off. *Trends Endocrinol. Metab.* 21, 142–150.
- Darlington, T.K., Wager-Smith, K., Ceriani, M.F., Staknis, D., Gekakis, N., Steeves, T.D., Weitz, C.J., Takahashi, J.S., and Kay, S.A. (1998). Closing the circadian loop: CLOCK-induced transcription of its own inhibitors per and tim. *Science* 280, 1599–1603.
- Deter, R.L., and De Duve, C. (1967). Influence of glucagon, an inducer of cellular autophagy, on some physical properties of rat liver lysosomes. *J. Cell Biol.* 33, 437–449.
- Eckel-Mahan, K.L., Patel, V.R., de Mateo, S., Orozco-Solis, R., Ceglia, N.J., Sahar, S., Dilag-Penilla, S.A., Dyar, K.A., Baldi, P., and Sassone-Corsi, P. (2013). Reprogramming of the circadian clock by nutritional challenge. *Cell* 155, 1464–1478.
- Gekakis, N., Staknis, D., Nguyen, H.B., Davis, F.C., Wilsbacher, L.D., King, D.P., Takahashi, J.S., and Weitz, C.J. (1998). Role of the CLOCK protein in the mammalian circadian mechanism. *Science* 280, 1564–1569.
- Godinho, S.I., Maywood, E.S., Shaw, L., Tucci, V., Barnard, A.R., Busino, L., Pagano, M., Kendall, R., Quwailid, M.M., Romero, M.R., et al. (2007). The after-hours mutant reveals a role for Fbxl3 in determining mammalian circadian period. *Science* 316, 897–900.
- Griffin, E.A., Jr., Staknis, D., and Weitz, C.J. (1999). Light-independent role of CRY1 and CRY2 in the mammalian circadian clock. *Science* 286, 768–771.
- Guex, N., and Peitsch, M.C. (1997). SWISS-MODEL and the Swiss-PdbViewer: an environment for comparative protein modeling. *Electrophoresis* 18, 2714–2723.
- Guillaumond, F., Dardente, H., Giguere, V., and Cermakian, N. (2005). Differential control of Bmal1 circadian transcription by REV-ERB and ROR nuclear receptors. *J. Biol. Rhythms* 20, 391–403.
- He, C., and Klionsky, D.J. (2009). Regulation mechanisms and signaling pathways of autophagy. *Annu. Rev. Genet.* 43, 67–93.
- Hirano, A., Yumimoto, K., Tsunematsu, R., Matsumoto, M., Oyama, M., Kozuka-Hata, H., Nakagawa, T., Lanjakornsiripan, D., Nakayama, K.I., and Fukada, Y. (2013). FBXL21 regulates oscillation of the circadian clock through ubiquitination and stabilization of cryptochromes. *Cell* 152, 1106–1118.
- Jang, H., Lee, G.Y., Selby, C.P., Lee, G., Jeon, Y.G., Lee, J.H., Cheng, K.K., Titchenell, P., Birnbaum, M.J., Xu, A., et al. (2016). SREBP1c-CRY1 signalling represses hepatic glucose production by promoting FOXO1 degradation during refeeding. *Nat. Commun.* 7, 12180.
- Jin, J., Cardozo, T., Lovering, R.C., Elledge, S.J., Pagano, M., and Harper, J.W. (2004). Systematic analysis and nomenclature of mammalian F-box proteins. *Genes Dev.* 18, 2573–2580.
- Karsli-Uzunbas, G., Guo, J.Y., Price, S., Teng, X., Laddha, S.V., Khor, S., Kalaany, N.Y., Jacks, T., Chan, C.S., Rabinowitz, J.D., et al. (2014). Autophagy is required for glucose homeostasis and lung tumor maintenance. *Cancer Discov.* 4, 914–927.
- Kern, L., Spreckels, J., Nist, A., Stiewe, T., Skevaki, C., Greene, B., Mernberger, M., and Elsasser, H.P. (2016). Altered glycogen metabolism

- causes hepatomegaly following an Atg7 deletion. *Cell Tissue Res.* 366, 651–665.
- Komatsu, M., Waguri, S., Chiba, T., Murata, S., Iwata, J., Tanida, I., Ueno, T., Koike, M., Uchiyama, Y., Kominami, E., et al. (2006). Loss of autophagy in the central nervous system causes neurodegeneration in mice. *Nature* 441, 880–884.
- Koo, S.H., Flechner, L., Qi, L., Zhang, X., Srean, R.A., Jeffries, S., Hedrick, S., Xu, W., Boussouar, F., Brindle, P., et al. (2005). The CREB coactivator TORC2 is a key regulator of fasting glucose metabolism. *Nature* 437, 1109–1111.
- Kume, K., Zylka, M.J., Sriram, S., Shearman, L.P., Weaver, D.R., Jin, X., Maywood, E.S., Hastings, M.H., and Reppert, S.M. (1999). mCRY1 and mCRY2 are essential components of the negative limb of the circadian clock feedback loop. *Cell* 98, 193–205.
- Lamia, K.A., Papp, S.J., Yu, R.T., Barish, G.D., Uhlenhaut, N.H., Jonker, J.W., Downes, M., and Evans, R.M. (2011). Cryptochromes mediate rhythmic repression of the glucocorticoid receptor. *Nature* 480, 552–556.
- Lamia, K.A., Sachdeva, U.M., DiTacchio, L., Williams, E.C., Alvarez, J.G., Egan, D.F., Vasquez, D.S., Juguilon, H., Panda, S., Shaw, R.J., et al. (2009). AMPK regulates the circadian clock by cryptochrome phosphorylation and degradation. *Science* 326, 437–440.
- Marcheva, B., Ramsey, K.M., Buhr, E.D., Kobayashi, Y., Su, H., Ko, C.H., Ivanova, G., Omura, C., Mo, S., Vitaterna, M.H., et al. (2010). Disruption of the clock components CLOCK and BMAL1 leads to hypoinsulinaemia and diabetes. *Nature* 466, 627–631.
- Martinez-Lopez, N., Garcia-Macia, M., Sahu, S., Athanvarangkul, D., Liebling, E., Merlo, P., Cecconi, F., Schwartz, G.J., and Singh, R. (2016). Autophagy in the CNS and periphery coordinate lipophagy and lipolysis in the brown adipose tissue and liver. *Cell Metab.* 23, 113–127.
- Marzella, L., Ahlberg, J., and Glaumann, H. (1982). Isolation of autophagic vacuoles from rat liver: morphological and biochemical characterization. *J. Cell Biol.* 93, 144–154.
- Meng, Q.J., Logunova, L., Maywood, E.S., Gallego, M., Lebiecki, J., Brown, T.M., Sladek, M., Semikhodskii, A.S., Glossop, N.R., Piggins, H.D., et al. (2008). Setting clock speed in mammals: the CK1 epsilon tau mutation in mice accelerates circadian pacemakers by selectively destabilizing PERIOD proteins. *Neuron* 58, 78–88.
- Michael, A.K., Fribourgh, J.L., Chelliah, Y., Sandate, C.R., Hura, G.L., Schneidman-Duhovny, D., Tripathi, S.M., Takahashi, J.S., and Partch, C.L. (2017). Formation of a repressive complex in the mammalian circadian clock is mediated by the secondary pocket of CRY1. *Proc. Natl. Acad. Sci. USA* 114, 1560–1565.
- Park, C., Suh, Y., and Cuervo, A.M. (2015). Regulated degradation of Chk1 by chaperone-mediated autophagy in response to DNA damage. *Nat. Commun.* 6, 6823.
- Perelis, M., Marcheva, B., Ramsey, K.M., Schipma, M.J., Hutchison, A.L., Taguchi, A., Peek, C.B., Hong, H., Huang, W., Omura, C., et al. (2015). Pancreatic beta cell enhancers regulate rhythmic transcription of genes controlling insulin secretion. *Science* 350, aac4250.
- Preitner, N., Damiola, F., Lopez-Molina, L., Zakany, J., Duboule, D., Albrecht, U., and Schibler, U. (2002). The orphan nuclear receptor REV-ERB α controls circadian transcription within the positive limb of the mammalian circadian oscillator. *Cell* 110, 251–260.
- Puigserver, P., Rhee, J., Donovan, J., Walkey, C.J., Yoon, J.C., Oriente, F., Kitamura, Y., Altomonte, J., Dong, H., Accili, D., et al. (2003). Insulin-regulated hepatic gluconeogenesis through FOXO1-PGC-1 α interaction. *Nature* 423, 550–555.
- Rodriguez-Muela, N., Koga, H., Garcia-Ledo, L., de la Villa, P., de la Rosa, E.J., Cuervo, A.M., and Boya, P. (2013). Balance between autophagic pathways preserves retinal homeostasis. *Aging Cell* 12, 478–488.
- Rubinstein, D.C., Marino, G., and Kroemer, G. (2011). Autophagy and aging. *Cell* 146, 682–695.
- Sahu, R., Kaushik, S., Clement, C.C., Cannizzo, E.S., Scharf, B., Follenzi, A., Potolicchio, I., Nieves, E., Cuervo, A.M., and Santambrogio, L. (2011). Microautophagy of cytosolic proteins by late endosomes. *Dev. Cell* 20, 131–139.
- Sangoram, A.M., Saez, L., Antoch, M.P., Gekakis, N., Staknis, D., Whiteley, A., Fruechte, E.M., Vitaterna, M.H., Shimomura, K., King, D.P., et al. (1998). Mammalian circadian autoregulatory loop: a timeless ortholog and mPer1 interact and negatively regulate CLOCK-BMAL1-induced transcription. *Neuron* 21, 1101–1113.
- Sato, T.K., Panda, S., Miraglia, L.J., Reyes, T.M., Rudic, R.D., McNamara, P., Naik, K.A., FitzGerald, G.A., Kay, S.A., and Hogenesch, J.B. (2004). A functional genomics strategy reveals Rora as a component of the mammalian circadian clock. *Neuron* 43, 527–537.
- Siepk, S.M., Yoo, S.H., Park, J., Song, W., Kumar, V., Hu, Y., Lee, C., and Takahashi, J.S. (2007). Circadian mutant Overtime reveals F-box protein FBXL3 regulation of cryptochrome and period gene expression. *Cell* 129, 1011–1023.
- Singh, R., Kaushik, S., Wang, Y., Xiang, Y., Novak, I., Komatsu, M., Tanaka, K., Cuervo, A.M., and Czaja, M.J. (2009). Autophagy regulates lipid metabolism. *Nature* 458, 1131–1135.
- Wahlquist, C., Jeong, D., Rojas-Munoz, A., Kho, C., Lee, A., Mitsuyama, S., van Mil, A., Park, W.J., Sluijter, J.P., Doevendans, P.A., et al. (2014). Inhibition of miR-25 improves cardiac contractility in the failing heart. *Nature* 508, 531–535.
- Xing, W., Busino, L., Hinds, T.R., Marionni, S.T., Saifee, N.H., Bush, M.F., Pagano, M., and Zheng, N. (2013). SCF(FBXL3) ubiquitin ligase targets cryptochromes at their cofactor pocket. *Nature* 496, 64–68.
- Yoo, S.H., Mohawk, J.A., Siepk, S.M., Shan, Y., Huh, S.K., Hong, H.K., Kornblum, I., Kumar, V., Koike, N., Xu, M., et al. (2013). Competing E3 ubiquitin ligases govern circadian periodicity by degradation of CRY in nucleus and cytoplasm. *Cell* 152, 1091–1105.
- Zhang, E.E., Liu, Y., Dentin, R., Pongsawakul, P.Y., Liu, A.C., Hirota, T., Nusinow, D.A., Sun, X., Landais, S., Kodama, Y., et al. (2010). Cryptochrome mediates circadian regulation of cAMP signaling and hepatic gluconeogenesis. *Nat. Med.* 16, 1152–1156.
- Zwighaft, Z., Aviram, R., Shalev, M., Rousso-Noori, L., Kraut-Cohen, J., Golik, M., Brandis, A., Reinke, H., Aharoni, A., Kahana, C., et al. (2015). Circadian clock control by polyamine levels through a mechanism that declines with age. *Cell Metab.* 22, 874–885.

STAR★METHODS

KEY RESOURCES TABLE

REAGENT or RESOURCE	SOURCE	IDENTIFIER
Antibodies		
Rabbit polyclonal anti-ATG7	Cell Signaling Technology	Cat# 2631; RRID: AB_2227783
Rabbit monoclonal anti-BMAL1	Cell Signaling Technology	Cat# 14020; RRID: AB_2728705
Rabbit monoclonal anti-CLOCK	Cell Signaling Technology	Cat# 5157; RRID:AB_10695411
Rabbit polyclonal anti-CRY1	Origene	Cat# TA342728
Rabbit polyclonal anti-CRY2	Abcam	Cat# ab38872, RRID: AB_731755
Mouse monoclonal anti-DYKDDDDK Tag	Cell Signaling Technology	Cat# 8146S; RRID: AB_10950495
Rabbit polyclonal anti-Fbxl3	Abcam	Cat# ab96645, RRID: AB_10679381
Rabbit polyclonal anti-G6Pase	Abcam	Cat# ab83690, RRID: AB_1860503
Rat monoclonal anti-LAMP1	DSHB	Cat# 1d4b, RRID: AB_2134500
Rabbit polyclonal anti-LC3B	Cell Signaling Technology	Cat# 2775; RRID: AB_915950
Human polyclonal anti-p62	Enzo Life Sciences	Cat# BML-PW9860, RRID: AB_2196009
Rabbit polyclonal anti-Pyruvate Carboxylase	Novus	Cat# NBP1-49536, RRID: AB_10011589
Rabbit polyclonal anti-PER1	Novus	Cat# NBP2-24589
Rabbit polyclonal anti-PER2	Origene	Cat# TA337016
Rabbit monoclonal anti-Rev-erb α	Cell Signaling Technology	Cat# 13418, RRID: AB_2630359
Rabbit polyclonal anti-Skp1	Cell Signaling Technology	Cat# 2156S; RRID: AB_10692507
Rabbit polyclonal anti-Fbxl3	Abcam	Cat# ab96645, RRID: AB_10679381
Rabbit polyclonal anti-Fbxl21	Abcam	Cat# ab222894
Secondary HRP Antibody Rabbit anti-Mouse IgG	Invitrogen	Cat# 61-6520, RRID: AB_2533933
Secondary HRP Antibody Goat anti-Rabbit IgG	KPL	074-1506
Goat anti-Rabbit IgG (H+L) Secondary Antibody, Alexa Fluor 488 conjugate	Thermo Fisher Scientific	Cat# R37116, RRID: AB_2556544
Goat anti-Rat IgG (H+L) Cross-Adsorbed Secondary Antibody, Alexa Fluor 647	Thermo Fisher Scientific	Cat# A-21247, RRID: AB_141778
Bacterial and Virus Strains		
pMC1SG5_mmCry1	Addgene	31282
mLIR1-CRY1 (²⁷¹ DLAKKA ²⁷⁶)	GenScript	N/A
mLIR2-CRY1 (²⁸⁵ SLAQQA ²⁹⁰)	GenScript	N/A
mLIR3-CRY1 (⁴⁸⁶ QIAQQA ⁴⁹¹)	GenScript	N/A
mLIR4-CRY1 (⁴⁹² SRARGA ⁴⁹⁷)	GenScript	N/A
AAV-TBG-GFP	Vector Biolabs	VB1743
AAV-TBG-iCre	Vector Biolabs	VB1724
Ad-CMV-Null	Vector Biolabs	1300
Ad-m-CRY1-shRNA	Vector Biolabs	shADV-256159
Chemicals, Peptides, and Recombinant Proteins		
High Fat Diet (60% of calories in fat)	Research Diets	D12492
Leupeptin hemisulfate	Fisher Scientific	BP2662100
Metrizamide	Sigma-Aldrich	860506
Trizol Reagent	Invitrogen	15596018
Triton X-100	Sigma-Aldrich	X100-500ml
Superscript II Reverse Transcriptase	Invitrogen	18064014
Sodium Pyruvate	Sigma-Aldrich	P2256
Power SYBR Green PCR Master Mix	Invitrogen	4368708
RNeasy Plus Mini kit	Qiagen	74136

(Continued on next page)

Continued

REAGENT or RESOURCE	SOURCE	IDENTIFIER
30% Acrylamide/ Bis Solution 37-5-1	BioRad	161-0158
Paraformaldehyde	Electron Microscopy Sciences	15714-S
Sodium Pyrophosphate	Sigma-Aldrich	AB02014
Sodium Chloride	AmericanBio	AB01915
β -Glycerophosphate	Sigma-Aldrich	G9891
Sodium Orthovanadate	Sigma-Aldrich	S6508
PMSF	Sigma-Aldrich	10837091001
Sucrose	AmericanBio	AB01900-01000
Super Signal West Femto Maximum Sensitivity Substrate, ECL	Pierce	34096
DAPI Fluoromount-G	SouthernBiotech	0100-20
Critical Commercial Assays		
NE-PER Nuclear and Cytoplasmic Extraction Reagents	Thermo Fisher Scientific	78835
Experimental Models: Organisms/Strains		
Mouse: C57BL/6 wildtype	The Jackson Laboratory	JAX: 000664
Mouse <i>Atg7^{flox/flox}</i>	Komatsu et al. (2006)	N/A
Oligonucleotides		
RT-PCR primers Please see Table S1	Sigma-Aldrich	N/A
Software and Algorithms		
ImageJ	NIH	https://imagej.nih.gov/ij/index.html ; RRID: SCR_003070
Prism	Graph Pad	https://www.graphpad.com/scientificsoftware/prism/ ; RRID: SCR_002798
Other		
StepOne Plus Real-Time PCR System	Thermo Fisher Scientific	4376600
CLAMS open-circuit indirect calorimetry	Columbus Instruments	N/A
Leica SP5 AOBS Inverted DMI6000 confocal microscope	Leica Microsystems	N/A
Ascensia Contour Glucometer	Bayer	7151H
Ascensia Contour strips	Bayer	7080G

CONTACT FOR REAGENT AND RESOURCE SHARING

Further information and requests for resources and reagents should be directed to the Lead Contact, Rajat Singh (rajat.singh@einstein.yu.edu).

EXPERIMENTAL MODEL AND SUBJECT DETAILS**Animals**

Studies were performed in 4-6-month-old male C57BL/6 mice, and *Atg7^{flox/flox}* mice ([Komatsu et al., 2006](#)) that was a kind gift from Drs. M. Komatsu and K. Tanaka, Tokyo Metropolitan Institute of Medical Science, Japan). *Atg7^{flox/flox}* mice were on the C57BL/6 background. Mice were used under a protocol approved by the Institutional Animal Care and Use Committee. Mice were fed a regular chow (5058; Lab Diet, St Louis, MO) or 8 weeks of HFD providing 60% calories in fat D12492; Research Diets, New Brunswick, NJ, USA. No inclusion/exclusion criteria were used in the selection of mice for the study.

Housing

Mice were maintained at 22-23°C on 12 hr light/dark cycles (7am-7pm) in the institutional barrier facility along with sentinel cages and are specific pathogen-free. Mice in sentinel cages are routinely tested by the Institute for Animal Studies for specific pathogens, and health reports are evaluated at regular intervals to determine whether rodents are pathogen-free or whether a specific treatment is required.

METHOD DETAILS

Autophagy Flux Assay

Autophagy/LC3-II flux was performed by intraperitoneal (i.p.) injection of lysosomal inhibitor (Lys Inh), leupeptin, at 40mg/kg mouse weight injected 2 hr prior to liver collection at 7am, 11am, 3pm, 7pm, 11pm and 3am. Livers were homogenized in a buffer containing protease and phosphatase inhibitors and immunoblotted for LC3. Autophagy flux was calculated by subtracting the densitometry values of LC3-II or p62 in Lys Inh-untreated from Lys Inh-treated samples (Martinez-Lopez et al., 2016).

Isolation of Autophagic Structures and Nuclear Fractions

Autophagosomes (Aph) and lysosomes (Lys) were isolated from livers by differential centrifugation using discontinuous density gradients of metrizamide. Briefly, liver homogenates were centrifuged at 2,000 *g* for 5 min followed by centrifugation of supernatants at 17,000 *g* for 12 min. We resuspended the pellets in 1.9 ml 0.25 M sucrose and then 2.8 ml of metrizamide (85.6%) was added. We centrifuged samples on a 26–24–20–15% metrizamide gradient at 75,334 *g* for 3 hr, following which the Aph fraction was collected from 15–20% interface, and Lys fraction from the 24–26% interface. Fractions were centrifuged at 24,000 *g* and pellets were resuspended in 0.25 M sucrose and analyzed. Cytosolic and nuclear fractions were isolated using ProteoExtract subcellular proteome extraction kit (EMD Millipore, Billerica, MA) as per manufacturer's instructions. Equivalent protein loading was verified using Ponceau and antibodies for Lamin A/C (nucleus), LC3-II (Aph), and LAMP1 (Lys).

RNA Isolation and qPCR Analyses

Total RNA was isolated using the Trizol Reagent (Invitrogen). The aqueous phase containing the RNA was loaded onto a gDNA Eliminator Spin Column (Qiagen, USA) to eliminate genomic DNA, and RNA was isolated using the RNeasy Plus kit (Qiagen) according to manufacturer's instructions. Total RNA (1 μ g) was reverse transcribed into cDNA using Superscript II (Invitrogen), and quantitative RT-PCR analyses was performed using Power SYBR Green PCR Master Mix (Applied Biosystems, UK) on a StepOne Plus Real-Time PCR System (Applied Biosystems, UK). Values were normalized to expression of the housekeeping gene TATA-binding protein (TBP). The mRNA expression in control samples was considered as 1 and mRNA expression in experimental samples was represented as fold-change compared to expression in controls. Comparisons were only made for expression levels between the same gene in control or KO samples. All reactions were performed in triplicate. Values were expressed in arbitrary units (a.u).

Plasmids and Adeno-Associated Virus (AAV) Injections *In Vivo*

Wildtype (WT) CRY1 plasmid (pMC1SG5_mmCry1) was a gift from Dr. Aziz Sancar (Addgene plasmid #31282) (5). CRY1 mLIR1-4 mutant plasmids were generated by site-directed mutagenesis (GenScript USA, Piscataway, NJ) and individual LIR mutations were validated by sequencing. We injected 50 μ g of WT FLAG-tagged CRY1 or mLIR CRY1 plasmids via tail vein injections using the *in vivo* jet polyethylenimine (PEI) transfection reagent (Polyplus-transfection, NY) as per manufacturer's protocols (Chang et al., 2014; Wahlquist et al., 2014). Mice were injected at 8am and sacrificed at 7pm. Expression of the plasmid in liver was determined by immunoblotting or RT-PCR analyses. Deletion of *Atg7* in liver was accomplished by tail vein injections of 109 PFU of AAVs expressing Cre recombinase and mice were humanely killed 7–13 days after injection. Knockdown of CRY1 in liver was accomplished by 10^{10} PFU of adenoviruses expressing CRY1-shRNA purchased from Vector Biolabs (Malvern, PA, USA) and injected 2 days prior to tissue collection.

Plasmid Transfections *In Vitro*

Cells (293T) were co-transfected with 0.5 μ g of GFP-tagged LC3 and 0.5 μ g FLAG-tagged WT-CRY1 or mutant CRY1 by lipofectamine 3000. After 36 hr of transfection, cells were lysed and precipitated with FLAG M2 gel (Sigma-Aldrich) and eluted with FLAG peptide (Sigma-Aldrich). Protein samples (10 μ g) were resolved in 4–10% gradient gels and then transferred and membranes were probed with anti-FLAG antibody (Sigma-Aldrich) and GFP antibody (Cell Signaling technology). Plasmid only control samples were transfected with pcDNA3 plasmid.

Pyruvate Tolerance Test (PTT)

Mice were fasted at noon and PTT was performed at 6pm, after i.p. injections of sodium pyruvate (1.5 g/kg body weight). Blood glucose levels were measured immediately prior to injection and at indicated timepoints after pyruvate injection using an Ascensia Contour glucometer (Bayer).

Western Blotting

Total protein from liver was isolated in buffer containing 20mM Tris, pH 7.5, 1% Triton X-100, 1mM EDTA, 1mM EGTA, and protease/phosphatase inhibitors. Lysates were centrifuged, and supernatants were subjected to immunoblotting by denaturing 20–50 μ g of protein at 100°C for 5 min in Laemmli sample buffer containing 62.5mM Tris, 2% SDS, 25% glycerol, 0.01% bromophenol blue, and 5% β -mercaptoethanol. Samples were resolved on SDS-PAGE and transferred to nitrocellulose membranes (GE Healthcare, USA) in transfer buffer containing 25mM Tris, 192mM glycine, 0.01% SDS, and 15% methanol using a Bio-Rad semidry transfer cell at 150mA for 90 minutes. Membranes were blocked in 5% nonfat dry milk, 20mM Tris, 500mM sodium chloride, and 0.5% Tween-20 for 1 hr and probed with primary antibodies.

Indirect Immunofluorescence

Livers were fixed with 4% paraformaldehyde, blocked and incubated with primary and corresponding secondary antibodies (Alexa Fluor 488 and/or Alexa Fluor 647 conjugated) (Invitrogen). Mounting medium contained DAPI (4',6-diamidino-2-phenylindole) to visualize the nucleus (Invitrogen). Images were acquired on a Leica SP5 AOBS Inverted DMI6000 confocal microscope (Leica Microsystems, Germany) using X63/1.4 oil objective. Images in each experiment were acquired at same exposure times within the same imaging session. All images were prepared using Adobe Photoshop and subjected to identical post-acquisition manipulations. Representative native images are shown. Quantification was performed after appropriate thresholding using the ImageJ software (NIH) in a minimum of 30 cells from three or more experiments. Cellular fluorescence intensity was expressed as mean integrated density as a function of individual cell size. Percentage colocalization was calculated using the JACoP plugin in single Z-stack sections of native images. Acquisition and quantification of images were performed in a blinded manner.

Assessments of Circadian Feeding Patterns

Circadian feeding patterns were assessed in CLAMS/metabolic cages (Columbus Instruments, USA).

Biochemical Analyses

Serum Insulin and Glucagon (ALPCO, NH, USA) and liver glycogen levels (Sigma Aldrich, USA) were assessed using commercial kits according to manufacturer's instructions.

QUANTIFICATION AND STATISTICAL ANALYSIS

Mean and standard error were calculated for each studied variable. Statistical significance was determined using One-way or Two-way ANOVA followed by Bonferroni multiple comparison test or by two-tailed unpaired Student's t-test. * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$ and ### $P < 0.001$. We performed the Shapiro-Wilk test to determine the normal distribution of the variables being tested. All statistical analyses were performed using Prism Graph Pad (La Jolla, CA). Statistical details for each experiment including n value are provided in the Figure legend.